Sold as Cienby. Every FDA application for this active ingredient.
As of Nov 22, 2026, FDA lists 1 application for Trisodium citrate (sold as Cienby), first approved Oct 19, 2026, with 0 new uses approved and 0 published complete response letters.
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Oct 19, 2026 | CienbyNDA 219455 · New active ingredient | Fresenius Medical Care | 0 | Marketed |
Of the 41 whose ending is known, 32% met their primary endpoint, 24% missed it and 44% stopped early.
| FIA Acute InflammationInflammation, Iron Absorption · University of Zurich | Not applicable | Not yet recruiting | Nov 12, 2026 |
| Study to Test Shorter Duration Chemoradiation Therapy Versus Standard Duration Chemoradiation Therapy for Cervical CancerCervical Adenocarcinoma, Cervical Adenosquamous Carcinoma · NRG Oncology | Phase 3 | Not yet recruiting | Nov 10, 2026 |
| Platelet-Rich Plasma for Bone Healing in Maxillary and Mandibular FracturesMandibular Fractures, Maxillary Fractures · CMH Lahore Medical College and Institute of Dentistry | Not applicable | Recruiting | Nov 10, 2026 |
| Induction Chemoimmunotherapy to Prevent Laryngectomy in Advanced Laryngeal Cancer and Hypopharyngeal CancerAdvanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma · Mayo Clinic | Phase 2 | Not yet recruiting | Nov 9, 2026 |
| Tislelizumab Combined With Tofacitinib and Docetaxel for NSCLC After Failure of First-Line ImmunotherapyPatients With Locally Advanced or Metastatic NSCLC Who Have Failed First-line Immunotherapy · Anhui Provincial Hospital | Phase 2 | Recruiting | Nov 9, 2026 |
| Magnesium Kinetics During Citrate-Anticoagulated CRRTContinuous Renal Replacement Therapy (CRRT), Magnesium · Region Skane | — | Not yet recruiting | Oct 30, 2026 |
| Effects of Daily Magnesium Complex Supplementation on Body Composition in University StudentsBody Composition Changes, Muscle Mass · Noakhali Science and Technology University | Not applicable | Not yet recruiting | Oct 30, 2026 |
| Post-Marketing Surveillance to Evaluate the Safety and Effectiveness of Zastaprazan CitrateErosive Gastroesophageal Reflux Disease · Jeil Pharmaceutical Co., Ltd. | — | Recruiting | Oct 26, 2026 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA